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A B S T R A C T
We recently reported that cluster determinant 36 (CD36), a fatty acid transporter, plays a pivotal role in
glucotoxicity-induced β-cell dysfunction. However, little is known about how glucotoxicity inﬂuences CD36
expression. Emerging evidence suggests that the small GTPase Rac1 is involved in the pathogenesis of beta cell
dysfunction in type 2 diabetes (T2D). The primary objective of the current study was to determine the role of
Rac1 in CD36 activation and its impact on β-cell dysfunction in diabetes mellitus. To address this question, we
subjected INS-1 cells and human beta cells (1.1B4) to high glucose conditions (30 mM) in the presence or
absence of Rac1 inhibition either by NSC23766 (Rac1 GTPase inhibitor) or small interfering RNA. High glucose
exposure in INS-1 and human beta cells (1.1b4) resulted in the activation of Rac1 and induced cell apoptosis.
Rac1 activation mediates NADPH oxidase (NOX) activation leading to elevated ROS production in both cells.
Activation of the Rac1-NOX complex by high glucose levels enhanced CD36 expression in INS-1 and human
1.1b4 beta cell membrane fractions. The inhibition of Rac1 by NSC23766 inhibited NADPH oxidase activity and
ROS generation induced by high glucose concentrations in INS-1 & human 1.1b4 beta cells. Inhibition of Rac1-
NOX complex activation by NSC23766 signiﬁcantly reduced CD36 expression in INS-1 and human 1.1b4 beta
cell membrane fractions. In addition, Rac1 inhibition by NSC23766 signiﬁcantly reduced high glucose-induced
mitochondrial dysfunction. Furthermore, NADPH oxidase inhibition by VAS2870 also attenuated high glucose-
induced ROS generation and cell apoptosis. These results suggest that Rac1-NADPH oxidase dependent CD36
expression contributes to high glucose-induced beta cell dysfunction and cell death.
1. Introduction
Type 2 diabetes is a chronic disease resulting from the progressive
impairment of insulin resistance and insulin insensitivity in target
tissues. However, at the core of type 2 diabetes pathology is the
inability of β-cells to sustain a compensatory secretory response,
leading to β-cell dysfunction and death [1–3]. Although, the molecular
signals that trigger β-cell deterioration are unknown, recent experi-
mental evidence suggests that it may involve an increased response to
FFA arising from intra-abdominal fat stores [4,5]. Importantly, studies
suggest that dysfunction occurs in the presence of elevated glucose
levels [6]. These chronic increases in circulating lipids and glucose
levels contribute to impaired β-cell dysfunction and other forms of
tissue damage. Studies in Zucker diabetic fatty (ZDF) rats showed that
elevated lipid accumulation leads to β-cell destruction via apoptosis
[7]. Several studies have shown that fatty acids can induce β-cell death
via apoptosis, which was potentiated by glucose [8,9]. The underlying
molecular and cellular mechanisms by which glucotoxicty and lipo-
toxicity contributes to β-cell destruction and death in type 2 diabetes
are still under debate. Recently, we reported that fatty acid translocase
cluster determinant 36 (CD36), a membrane glycoprotein, inﬂuences
glucotoxicity dysfunction by increasing the inﬂux of free fatty acids into
pancreatic β-cells [10]. Moreover, forced expression of CD36 in β-cells
increases the uptake of fatty acids and leads to metabolic and
functional alterations [11,12]. However, the underlying molecular
and cellular mechanisms by which glucotoxicity contributes to CD36
induction and cell death in type 2 diabetes are not completely under-
stood.
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Rac1 is a small guanosine triphosphate (GTP)–bound protein
belonging to the Rho family. In particular, they are important
regulators of cytoskeletal dynamics and of a variety of cellular
processes, including cell polarization, morphogenesis, migration, apop-
tosis, vesicle traﬃcking, viral transport, and cellular transformation
[13]. Moreover, Rac1 signaling induces localized actin polymerization
at the membrane level, promoting the internalization of particles and
microorganisms, and contributes to the assembly and activation of the
phagocyte nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase complex involved in the elimination of bacteria [14]. Several
pieces of evidence support a key role for Rac1 in various phenomena in
the cytoskeleton, oxidative stress and insulin secretion. Because of its
diverse functions, Rac1 has both positive and negative impacts on
pancreatic beta cells [15]. One important eﬀector of Rac1 activity is
p67phox, which combines with other components of the NADPH
oxidase (NOX) system when activated to generate a fully functional
complex for producing ROS. Moreover, NOX has long been recognized
as a signaling molecule in the inﬂammatory response to the induction
of insulin resistance, both in vitro and in vivo [16,17]. Based on the
potential importance of NOX in the pathogenesis of type 2 diabetes, the
role of Rac1-NOX in beta-cell dysfunction and apoptosis remains
unknown.
In the present study, the eﬀects of Rac1-NADPH oxidase signaling
on CD36 activation were investigated in INS-1 and human pancreatic
1.1b4 beta cells. Our results showed that Rac1-NADPH oxidase
activation mediates CD36 expression induced by high levels of glucose.
Rac1-NADPH oxidase inhibition strongly blocked CD36 expression
and protected beta cells from apoptosis induced by high glucose levels
by suppressing mitochondrial dysfunction.
2. Materials and methods
2.1. Cell culture, chemicals
Rat insulinoma INS-1 cells and human pancreatic insulin-releasing
1.1b4 cells (passage 30–40; purchased from ECACC, European
Collection of Cell Cultures, Sigma-Aldrich, St. Louis, MO, USA) were
cultured in a humidiﬁed atmosphere containing 5% CO2 in RPMI 1640
(Life Technologies, Inc., Grand Island, NY) medium supplemented
with 10% (v/v) heat-inactivated FBS (Gibco, Grand Island, NY, USA),
100 U/ml penicillin and 100 μg/ml streptomycin. Lipofectamine™
2000 Transfection Reagent (Invitrogen, Carlsbad, CA) was used to
transfect INS-1 cells. Cells were transfected with 100 nmol/l of Rac1-
siRNA (Bioneer Corporation, Daejeon, Korea). After 24 h of transfec-
tion, the cells were exposed to 30 mM glucose for varying periods of
time.
2.2. Rac1 activation assay
Activation of Rac1 was quantiﬁed using a Rac1 activation assay kit
(Upstate Biotechnology). Brieﬂy, cells were serum starved and then
treated with NSC23766 (50 μM) for 2 h. Subsequently, cells were
treated with a high concentration of glucose (30 mM) for the indicated
time period. The plate was washed extensively. Protein samples were
prepared according to the manufacturer's instructions. Samples were
resolved using SDS-PAGE and transferred to a nitrocellulose mem-
brane. GTP-bound Rac1 was identiﬁed using the anti-Rac1 antibody.
2.3. NADPH oxidase activity assay
NADPH oxidase activity in cell lysates was assayed using the
lucigenin chemiluminescence assay according to methods described
Fig. 1. Eﬀects of high glucose concentrations on Rac1, NADPH oxidase activity and apoptosis. (a) INS-1 cells were treated with high concentrations of glucose (30 mM) for varying
periods of time. Rac1 activity was measured by Rac1-Upstate assay kit. (*P < 0.005 vs. Control). (b) INS-1 cells were treated with high concentrations of glucose (30 mM) for the
indicated time periods. NADPH oxidase activity was measured by lucigenin based assay. Data represent the mean ± SEM of three independent experiments. *P < 0.001 vs Control. (c)
INS-1 cells were treated with high concentrations of glucose (30 mM) for 24 h and apoptosis was assessed by TUNEL-assay using ﬂuorescence microscopy. The results are expressed as
the mean ± SEM. *P < 0.001 vs. Control.
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previously [18] with modiﬁcations. The cells were treated with
NSC23766 (50 μM) for 2 h and then exposed to high concentrations
of glucose (30 mM) for the indicated period of time. After incubation,
the cells were homogenized through sonication in PBS containing
1 mM MgCl2, 1 mM EGTA and protease inhibitors. The homogenates
were centrifuged at 3000g for 10 min at 4 °C. The cleared lysates
(250 μg/ml of protein) were then incubated with 20 μM lucigenin
(Cayman Chemicals) and 100 μM NADPH (Sigma Aldrich) prepared in
PBS. Chemiluminescence was measured every minute for 5 min using a
luminometer. NADPH oxidase activity was expressed in relative light
units (RLU) per μg protein. To detect the inhibitory eﬀects of NADPH
oxidase activity, cells were ﬁrst incubated with VAS-2870 (10 μM) for
1 h. Subsequent steps followed the same procedures detailed above.
2.4. Apoptosis and mitochondrial functional assay
INS-1 cell apoptosis was assessed using the TUNEL staining kit
(Roche, Basal, Switzerland). INS-1 cells were exposed to either vehicle
or NSC23766 (50 μM) for 2 h or VAS-2870 (10 μM) for 1 h and then
exposed to high concentrations of glucose (30 mM) for 24 h. Upon
completion of the treatment, the cells were further processed, accord-
ing to the manufacturer's instructions. The image was captured using
ﬂuorescence microscopy. Cell death was quantiﬁed using ImageJ
software (National Institute of Health). The mitochondrial membrane
potential was measured using DiOC6 (Sigma-Aldrich). Brieﬂy, har-
vested cells were washed once with PBS and then labeled with 10 nM
DiOC6 for 5 min at 37 °C. The cells were washed once and the cell
ﬂuorescence was analyzed using ﬂow cytometry (BD Biosciences, San
Jose, CA). Intracellular ROS generation was assessed using 2, 7-
dichlorodihydroﬂuorescein diacetate (DCF-DA, Molecular Probes,
Invitrogen, USA). INS-1 cells were washed and then incubated in the
dark for 15 min with 10 μM/l DCF-DA at 37 °C and then visualized
under a ﬂuorescence microscope. The mean ﬂuorescence intensity was
used to quantify cellular ROS. Apoptosis and mitochondrial dysfunc-
tion were conﬁrmed by assessing cytosolic cleaved caspase-3 and
cytochrome c release using western blot analysis. Cytoplasmic extract
were fractionated using the NE-PER Nuclear and Cytoplasmic
Extraction Reagent Kit (Thermo Scientiﬁc, Rockford, USA) according
to the instructions of the supplier.
2.5. Cell viability and caspase-3 activity
Human pancreatic 1.1b4 cells were pretreated with or without
NSC23766 (50 μM) for 2 h or VAS2870 (10 μM) for 1 h, followed by
stimulation with 30 mM glucose. After 48 h, the percentage of viable
cells were measured using the Cell Counting Kit-8 (CCK-8) (Dojindo
Lab., Kumamoto, Japan). Caspase-3 activity in the cell extracts was
determined using Caspase-Glo 3/7 Assay (Promega). The luminescence
of each sample was measured using Flex station (Molecular Devices).
Caspase 3/7 activity was expressed in terms of relative ﬂuorescence
units.
2.6. Plasma membrane preparation
INS-1 and human pancreatic 1.1b4 cell plasma membrane extracts
were prepared using a plasma membrane protein extraction kit
(Biovision). The cells were washed once in cold PBS and plasma
membrane protein extraction was performed according to the manu-
facturer's instructions using the reagents included in the kit. The
protein concentration was obtained using the Bradford protein assay.
NA+K+ATPASE was used as a loading control to show the same
amounts of plasma membrane protein in each lane.
2.7. Western blotting
Cell protein lysates were resolved using NuPAGE 4–12% Bis-Tris
gel (Invitrogen) and transferred to PVDF membranes (Millipore,
Billerica, MA, USA). After blocking, the membranes were stored at
Fig. 2. Eﬀects of NSC23766 on Rac1 and NADPH oxidase activity. (a) INS-1 cells were treated with NSC23766 (50 μM) for 2 h and then exposed to high concentrations of glucose
(30 mM) for 1 h to measure Rac1 activity. (*P < 0.0001 vs. Control, **P < 0.005 vs. HG). (b) INS-1 cells were transfected with 100 nmol/l of Rac1-siRNA and then exposed to high
concentrations of glucose (30 mM) for 1 h. (*P < 0.0001 vs. Control, **P < 0.0001 vs. HG). (c) Cells were treated with NSC23766 (50 μM) for 2 h or transfected with Rac1-siRNA and then
exposed to high concentrations of glucose (30 mM) for 3 h. NADPH oxidase activity was measured by lucigenin based assay. Values represent the means ± SEM. (*P < 0.001 vs. Control,
**P < 0.001 vs. HG).
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4 °C with the following primary antibodies: NA+K+ATPASE, phospho
JNK, p38 MAPK, cleaved caspase 3 (Cell signaling Technology,
Danvers, MA, USA), CD36 (Cayman Chemicals, Ann Arbor, MI,
USA), Rac1, cytochrome c (BD Biosciences, San Jose, CA, USA) and
actin (Abcam, Cambridge, UK). The membranes were then washed and
incubated with horseradish peroxidase (HRP)-conjugated secondary
antibodies. Immuno-reactive proteins were detected using ECL re-
agents (ECL Plus; Amersham, GE Healthcare Life Sciences, Little
Chalfont, Buckinghamshire, UK). Band densities were measured using
ImageJ software (NIH).
2.8. Statistical analysis
Statistical signiﬁcance was determined using the one-way Tukey
test or by the analysis of variance (ANOVA) as appropriate. P values <
0.05 were considered statistically signiﬁcant.
3. Results
3.1. Activation of Rac1, NADPH oxidase and induction of beta cell
apoptosis by high glucose concentrations
To determine whether high concentrations of glucose (30 mM) can
induce Rac1 activation, we treated INS-1 cells with high concentrations
of glucose for varying periods of time. As shown in Fig. 1a, a robust
elevation of Rac1 activity was observed at 60 min. High glucose-
induced Rac1 activity was associated with elevations in NADPH
oxidase activity as measured by the chemiluminescence assay
(Fig. 1b). Furthermore, treatment with high concentrations of glucose
signiﬁcantly induced INS-1 cell apoptosis (Fig. 1c).
3.2. NSC23766 inhibits Rac1, NADPH oxidase activation by high
glucose concentrations
To test whether inhibition of Rac1 improves beta cell function, we
treated INS-1 cells with the Rac1-GTPase inhibitor NSC23766 (50 μM)
for 2 h and then exposed them to high concentrations of glucose
(30 mM) for another 1 h. Treating INS-1 cells with NSC23766 (50 μM)
eﬀectively decreased Rac1 activity induced by high concentrations of
glucose(30 mM) (Fig. 2a). To conﬁrm whether the beta-cell dysfunction
induced by high glucose concentrations is mediated by Rac1, we
downregulated endogenous Rac1 expression by transfecting INS-1
cells with Rac1-siRNA and then incubating them in high concentra-
tions of glucose (30 mM) for 1 h. Rac1-siRNA signiﬁcantly inhibited
the endogenous Rac1 expression at the high glucose concentrations.
(Fig. 2b). Consistent with this ﬁnding, treatment of INS-1 cells with
either NSC23766 (50 μM) or Rac1-siRNA signiﬁcantly blocked high
glucose-induced NADPH oxidase activity (Fig. 2c). Moreover, treat-
Fig. 3. Eﬀects of NSC23766 on high glucose-induced CD36 expression. (a) Cells were treated with NSC23766 (50 μM) for 2 h and then exposed to high concentrations of glucose
(30 mM) for the indicated periods of time. Total cell lysates was used to measure CD36 expression by immunoblotting. *P < 0.001 vs. control, **P < 0.005 vs. HG. (b, c) The eﬀect of
NSC237669 (50 μM) or Rac1-siRNA on high glucose induced CD36 expression at plasma membrane fractionation was analyzed by immunoblotting. Cellular plasma membrane were
prepared using a plasma membrane protein extraction kit. NA+K+ATPASE was used as the loading control. *P < 0.0001 vs. control, *P < 0.001 vs. HG.
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ment of INS-1 cells with VAS-2870 (10 μM) reduced high glucose-
induced NADPH oxidase activity (Supplementary Fig. 1).
3.3. Induction of CD36 expression by high concentrations of glucose
and inhibition by NSC23766
In addition to the role of CD36 as a master transporter of fatty acid
uptake, evidence also suggests that CD36 plays a role in the regulation
of beta cell dysfunction [19]. Based on this ﬁnding, we speculated that
high glucose-induced upregulation of Rac1-NADPH oxidase activity
may induce CD36 expression. Consistent with this assumption, we
found that CD36 expression increased in a time dependent manner in
INS-1 cells after treatment with high concentrations of glucose
(Fig. 3a). We then examined the membrane translocation of CD36.
As shown in Fig. 3b, at 12 h the CD36 protein levels in the plasma
membranes were signiﬁcantly upregulated in high glucose-treated INS-
1 cells. Indeed, INS-1 cells treated with NSC23766 (50 μM) exhibited
time dependent decreases in CD36 expression (Fig. 3a). Additionally,
NSC23766 (50 μM) treatment signiﬁcantly decreased CD36 protein
expression in the plasma membrane fractionation (Fig. 3b). To
determine whether CD36 expression induced by high glucose concen-
trations (30 mM) is mediated by Rac1, we downregulated endogenous
Rac1 expression by transfecting INS-1 cells with Rac1-siRNA and then
incubated them with high concentrations of glucose (30 mM). Rac1-
siRNA signiﬁcantly inhibited high glucose-induced upregulation of
CD36 expression in the plasma membrane (Fig. 3c). These observa-
tions suggest that high glucose-induced CD36 expression is mediated
by Rac1 activation.
3.4. NSC23766 blocks mitochondrial dysfunction in beta cells by
suppressing Rac1-NADPH oxidase activity
Next, we determined whether Rac1 inhibition blocked high glucose-
induced mitochondrial dysfunction. The mitochondrial membrane
potential was assessed using ﬂow cytometry. Interestingly, Rac1
inhibition by NSC23766 (50 μM) abolished high glucose-induced
mitochondrial membrane potential loss followed by a release of
cytochrome c into the cytosol and caspase-3 activation, reﬂecting the
activation of the permeability transition pore (PTP), a key event in cell
death (Fig. 4a–c). High glucose-induced caspase-3 activation was also
blocked by the NADPH oxidase inhibitor VAS-2870 (10 μM)
(Supplementary Fig. 2). Intracellular ROS production plays a critical
role in mediating mitochondrial dysfunction and cell death [20−22]. As
shown in Fig. 4d, intracellular ROS levels were signiﬁcantly increased
by high glucose (30 mM). Interestingly, Rac1 inhibition by NSC23766
(50 μM) or Rac1-siRNA suppressed high glucose-induced intracellular
ROS in INS-1 cells (Fig. 4d). In addition, intracellular ROS production
was also decreased by the NADPH oxidase inhibitor VAS-2870(10 μM)
(Supplementary Fig. 3). Consistent with the changes in ROS levels,
high glucose-induced cell apoptosis was inhibited by Rac1 inhibition
(Fig. 4e) or NADPH oxidase inhibition (Supplementary Fig. 4).
3.5. High glucose induced Rac1 activation in human 1.1b4 beta cells
In an attempt to establish the eﬀects of high glucose concentrations
on Rac1 activation in human pancreatic beta cells, we treated human
pancreatic 1.1b4 beta cells with high levels of glucose (30 mM) for
24 h. As expected, treatment with high concentrations of glucose
resulted in Rac1 activation. In addition, pretreatment with
NSC23766 (50 μM) resulted in marked Rac1 inhibition (Fig. 5a). We
further detected that treatment with high concentrations of glucose
(30 mM) induces NADPH oxidase activity. These results indicated that
the Rac1 activity in 1.1b4 cells was also increased by high glucose
concentrations and that Rac1-induced activation of NADPH oxidase
activity was inhibited by NSC23766 (50 μM) (Fig. 5b). Consequently,
Rac1 activity mediated by high glucose concentrations increased CD36
expression in the membrane fraction of 1.1b4 cells. In addition,
NSC23766-mediated Rac1 inhibition decreased CD36 accumulation
(Fig. 5c). Combined, these results indicate that Rac1 inhibition blocks
CD36 expression in human pancreatic 1.1b4 cells.
3.6. Inhibition of Rac1 prevents high glucose-induced ROS, caspase-3
activity and cell viability loss
Given that Rac1 is a key regulator of NADPH oxidase activation and
superoxide O2
•− production, we determined whether intracellular ROS
production was aﬀected by high glucose concentrations and Rac1-
NADPH oxidase inhibition. As shown in Fig. 6a, when compared to the
control, high levels of glucose (30 mM) strongly increased intracellular
ROS production in 1.1b4 cells. This high glucose-induced ROS
production was abolished by either NSC23766 (50 μM) or VAS-2870
(10 μM) treatment. Rac1 or NADPH oxidase inhibition also inhibited
high glucose-induced caspase-3 activity in 1.1b4 cells (Fig. 6b).
Furthermore, we also examined the possibility that high glucose-
induced 1.1b4 cell viability loss would be prevented by Rac1-NADPH
oxidase inhibition. To a similar extent, inhibition of Rac1-NADPH
oxidase with NSC23766 (50 μM) or VAS-2870 (10 μM) signiﬁcantly
reduced high glucose-induced 1.1b4 cell viability loss (Fig. 6c). Taken
together, these results demonstrate that high glucose-mediated Rac1-
NADPH oxidase activation resulted in mitochondrial dysfunction and
the loss of cell viability.
4. Discussion
In the present study, we demonstrated high glucose-induced
toxicity in pancreatic beta cells by means of Rac1-NADPH oxidase
activation. Importantly, we showed that exposure of pancreatic beta
cells to high glucose concentrations induced CD36 expression through
Rac1-NADPH oxidase activation.
An accumulation of evidence suggests that hyperglycemia contri-
butes to pancreatic beta cell failure and the development of diabetes
[1−4]. Our previous study demonstrated that CD36 activation by high
glucose concentrations mediates beta cell dysfunction [10]. However,
the underlying mechanisms of CD36 activation remain unclear. To
identify the signaling pathway involved in CD36 activation of glucose,
we established a potential link between Rac1-NADPH oxidase and
Fig. 4. Inhibitory eﬀects of NSC23766 on high glucose-induced mitochondrial dysfunction. (a) INS-1 cells were treated with NSC23766 (50 μM) for 2 h and then exposed to high
concentrations of glucose (30 mM) for 24 h and then mitochondrial membrane potentials was analyzed by FACs using DiO6 dye; a representative FACs data shown in the upper panel
and the quantiﬁcation of the M1 ratio from three independent experiments shown in the lower panel. *P < 0.0001 vs. control, **P < 0.0001 vs. HG. (b, c) INS-1 cells were treated with
NSC23766 (50 μM) for 2 h and then exposed to high concentrations of glucose (30 mM) for 24 h. Cytoplasmic extract were fractionated using the NE-PER Nuclear and Cytoplasmic
Extraction Reagent Kit. Cytosolic cytochrome c and cleaved caspase-3 protein expression were analyzed by immunoblotting. *P < 0.0001 vs. control, #P < 0.001 vs. HG, **P < 0.005 vs.
HG. Data represents three independent experiments and equal loading was conﬁrmed with β-actin. (d) Inhibition of Rac1 activity blocks high glucose induced ROS production. INS-1
cells were treated with NSC23766 (50 μM) for 2 h or transfected with 100 nmol/L Rac1-siRNA and then exposed to high concentrations of glucose (30 mM) for 24 h. Cellular ROS
production was analyzed by ﬂuorescence microscopy using 10 μM/L DCF-DA. *P < 0.0001 vs. control, **P < 0.005 vs. HG, ***P < 0.001 vs. HG. (e) Inhibition of Rac1 activity blocks high
glucose induced INS-1 cell apoptosis. INS-1 cells were treated with NSC23766 (50 μM) for 2 h and then exposed to high concentrations of glucose (30 mM) for 24 h. INS-1 cell apoptosis
was assessed by TUNEL-assay using ﬂuorescence microscopy. *P < 0.001 vs. control, *P < 0.001 vs. HG.
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CD36 activation during beta cell dysfunction. Although Rac1-NADPH
oxidase signaling has been implicated in beta cell damage [16−18, 23],
its role in CD36 activation provides a link to the completely distinct
process of beta cell dysfunction. Overwhelming evidence suggests that
Rac1 inhibition may have protective eﬀects in beta cells exposed to
high concentrations of glucose [24]. In agreement with what has been
Fig. 5. Inhibitory eﬀects of NSC23766 on high glucose-induced Rac1, NADPH oxidase and CD36 activation in human 1.1b4 cells. (a, b) Human pancreatic 1.1b4 cells were incubated
with NSC23766 (50 μM) for 2 h and then exposed to high glucose concentrations (30 mM) for 24 h. Rac1 (*P < 0.05 vs. control, **P < 0.05 vs. HG) and NADPH oxidase (*P < 0.001 vs.
control, **P < 0.001 vs. HG) activity were measured as described in the methods section. The results represent the mean ± SEM of three independent experiments. (c) Human pancreatic
1.1b4 cells were treated with NSC23766 (50 μM) for 2 h and then exposed to high glucose concentrations (30 mM) for 24 h. Cellular plasma membrane extracts were prepared using a
plasma membrane protein extraction kit. Plasma membrane fractionation cell lysates were analyzed by western blotting with CD36 or NA+K+ATPASE antibodies. *P < 0.001 vs. control,
**P < 0.001 vs. HG. Data represents three independent experiments.
Fig. 6. NSC23766 inhibits high glucose induced ROS, Caspase-3 activity and cell viability loss in Human 1.1b4 cells. (a) Human pancreatic 1.1b4 cells were treated with NSC23766
(50 µM) for 2 h and VAS2870 (10 µM) for 1 h and then exposed to high glucose (30 mM) for 48 h. Cellular ROS production was analyzed by ﬂuorescence microscopy using 10 µM/l DCF-
DA. *P < 0.001 vs. control, **P < 0.001 vs. HG. (b) Human 1.1b4 cells were treated as mentioned above and caspase-3 activity was measured by Caspase-Glo 3/7 assay kit. Values
expressed as relative ﬂuorescence units. *P < 0.0001 vs. control, **P < 0.001 vs. HG. (c) Human pancreatic 1.1b4 cells were treated with NSC23766 (50 µM) for 2 h and VAS2870 (10 µM)
for 1 h and then exposed to high glucose (30 mM) for 48 h. Cell viability were measured using Cell Counting Kit-8 after experimental conditions. *P < 0.0001 vs. control, **P < 0.005 vs.
HG. The results are expressed as the means ± SEM of three independent experiments.
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previously found, we observed that Rac1 activation led to increased cell
apoptosis after exposure to high concentrations of glucose (30 mM).
Pharmacological inhibition of Rac1 by NSC23766 inhibited increases
in cell apoptosis. Moreover, inhibition of Rac1 activity using siRNAs
conﬁrmed these results. In addition to increased Rac1 activation,
exposure to high concentrations of glucose was also associated with
increased ROS production [25]. Interestingly, Rac1 plays a crucial role
in the activation of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, a membrane associated protein complex that
catalyzes the one electron reduction of oxygen to a superoxide anion
[26, 27]. With this functional characterization, we also tested the
eﬀects of high glucose concentrations on NADPH oxidase activity in
INS-1 as well as in human 1.1b4 cells. A signiﬁcant increase in NADPH
oxidase activity was observed in cells after exposure to high concentra-
tions of glucose; whereas Rac1 inhibition by NSC23766 strongly
inhibited increases in NADPH oxidase activity. NADPH oxidase activity
had similar inhibitory eﬀects in INS-1 cells after VAS-2870 treatment.
Our ﬁndings suggest that Rac1-NADPH oxidase is involved in the
metabolic dysfunction of beta cells under hyperglycemic conditions.
Several studies have demonstrated that hyperglycemia-induced
CD36 expression mediates cellular dysfunction in various tissues [28,
29]. This upregulation was found to coincide with increased oxidative
stress. With this functional characterization, we also tested the eﬀects
of high glucose concentrations on CD36 expression as well as its
traﬃcking to the plasma membrane. Of note, CD36 expression was
signiﬁcantly increased in INS-1 and human 1.1b4 pancreatic beta cells,
suggesting the pronounced cytotoxic eﬀects of high levels of glucose.
Moreover, increases in membrane CD36 were observed after treatment
with high concentrations of glucose reﬂect its function in cellular fatty
acid uptake. Recently, it has been shown that CD36 deﬁciency
attenuates obesity associated oxidative stress in the heart through
reduced NADPH oxidase activity [30]. Interestingly, pharmacological
inhibition of Rac1 by NSC23766 or siRNA attenuated high glucose
induced NADPH oxidase activity, suggesting the critical involvement of
NADPH oxidase in the activation of CD36 expression.
On the other hand, pharmacological and genetic inhibition of
NADPH oxidase prevent oleate-induced beta cell dysfunction [31].
These ﬁndings support the hypothesis that Rac1-NADPH oxidase
contributes to CD36 activation under hyperglycemic conditions.
Most strikingly, it is closely integrated with mitochondria, which
play an important role in high glucose-induced beta cell apoptosis [32,
33]. In support of this ﬁnding, altered mitochondrial membrane
potentials were found to be associated with the release of cytochrome
c leading to the activation of caspase-3, which reﬂects perturbations in
mitochondrial function imposed by high levels of glucose. Under the
same conditions, ROS generation in response to high levels of glucose
was increased. However, we show that Rac1 inhibition could counter-
act high glucose-induced mitochondrial dysfunction by inhibiting
mitochondrial membrane potential loss linked to the reduction of
cytochrome c release and caspase-3 activation. In addition, Rac1 and
NADPH oxidase inhibition depleted cellular ROS generation induced
by high concentrations of glucose. Moreover, it should be noted that
changing the balance of mitochondrial enzymes and increasing ROS
production can alter susceptibility to dysfunction by the activation of
stress kinases [34,35]. A recent study conducted by Sidarala et al. [36]
reported that Rac1-NADPH oxidase was associated with increases in
MAPK activation by glucotoxicity. Considering this, we found that high
concentrations of glucose induced MAPK activation while Rac1 inhibi-
tion blocked this activation (Supplementary Fig. 5).
Similar to our ﬁndings in INS-1 cells, we demonstrated that
prolonged exposure of human pancreatic 1.1b4 cell lines to high
concentrations of glucose resulted in Rac1 activation and increased
NADPH oxidase activity. Furthermore, we found that CD36 membrane
expression was signiﬁcantly increased by treatment with high concen-
trations of glucose in human 1.1b4 cells. Interestingly, similar inhibi-
tory eﬀects by NSC23766 on Rac1 activation were observed in human
1.1b4 cells. Moreover, Rac1 inhibition would have been suﬃcient to
inhibit high glucose-induced NADPH oxidase activity as well as CD36
membrane translocation. Finally, treatment of human 1.1b4 cells with
Rac1 or NADPH oxidase inhibitor prevented high glucose-induced ROS
production, caspase-3 activity and 1.1b4 cell viability loss. Our results
present the ﬁrst evidence that Rac1 inhibition protects human 1.1b4
cells from high glucose-induced apoptosis by blocking NADPH oxidase-
CD36 activation.
In conclusion, we clearly demonstrated that Rac1-NADPH oxidase
activation by high glucose-induced CD36 expression. The membrane
expression of CD36 may increase beta cell dysfunction by increasing
fatty acid uptake. Pharmacological or siRNA-mediated inhibition of
Rac1 prevents high glucose-induced pancreatic beta cell apoptosis by
blocking the NADPH oxidase-CD36-mitochondrial pathway (Fig. 7).
Future studies examining the precise relationship between Rac1 and
CD36 should address their potential interplay in the pancreatic beta
cell dysfunction and failure.
Funding
This study was supported by 2015 Yeungnam University Research
Grant (Kyu Chang Won) and Grant of the Korea Health Technology R
&D project, Ministry of Health and Welfare, Republic of Korea (In Kyu
Lee HI16C1501).
Appendix A. Supplementary material
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.redox.2016.11.009.
References
[1] S.C. Lee, S. Pervaiz, Apoptosis in the pathophysiology of diabetes mellitus, Int. J.
Biochem. Cell Biol. 39 (2007) 497–504.
Fig. 7. Rac1-NADPH oxidase induces CD36 expression under high glucose. High
glucose induced Rac1-NADPH oxidase complex induced CD36 traﬃcking to the plasma
membrane. Increased plasma membrane expression of CD36 may increase inﬂux of free
fatty acids into the cell and increase the dysfunction of beta cells. High levels of ROS
enhance the oxidative damage and exacerbate the beta cell apoptosis by mitochondrial
dysfunction.
S. Elumalai et al. Redox Biology 11 (2017) 126–134
133
[2] R.P. Robertson, J.S. Harmon, Diabetes, glucose toxicity, and oxidative stress: a case
of double jeopardy for the pancreatic islet ß cell, Free Radic. Biol. Med. 41 (2)
(2006) 177–184.
[3] J.L. Leahy, Pathogenesis of type 2 diabetes mellitus, Arch. Med. Res. 36 (2005)
197–209.
[4] R.P. Robertson, J. Harmon, P.O. Tran, V. Poitout, ß cell glucose toxicity,
lipotoxicity, and chronic oxidative stress in type 2 diabetes, Diabetes 53 (Suppl 1)
(2004) S119–S124.
[5] T.T. Goh, T.M. Mason, N. Gupta, A. So, T.K. Lam, L. Lam, G.F. Lewis, A. Mari,
A. Giacca, Lipid-induced ß-cell dysfunction in vivo in models of progressive ß-cell
failure, Am. J. Physiol. Endocrinol. Metab. 292 (2007) E549–E560.
[6] M. Dubois, J. Kerr-Conte, V. Gmyr, T. Bouckenooghe, G. Muharram,
M. D’Herbomez, A. Martin-Ponthieu, M.C. Vantyghem, B. Vandewalle, F. Pattou,
Non-esteriﬁed fatty acids are deleterious for human pancreatic islet function at
physiological glucose concentration, Diabetologia 47 (2004) 463–469.
[7] M. Shimabukuro, Y.T. Zhou, M. Levi, R.H. Unger, Fatty acid-induced ß cell
apoptosis: a link between obesity and diabetes, Proc. Natl. Acad. Sci. USA 3 (1998)
2498–2502.
[8] K. Maedler, J. Oberholzer, P. Bucher, G.A. Spinas, M.Y. Donath, Monounsaturated
fatty acids prevent the deleterious eﬀects of palmitate and high glucose on human
pancreatic ß-cell turnover and function, Diabetes 52 (2003) 726–733.
[9] K. Maedler, G.A. Spinas, D. Dyntar, W. Moritz, N. Kaiser, M.Y. Donath, Distinct
eﬀects of saturated and monounsaturated fatty acids on ß-cell turnover and
function, Diabetes 50 (2001) 69–76.
[10] Y.W. Kim, J.S. Moon, Y.J. Seo, S.Y. Park, J.Y. Kim, J.S. Yoon, I.K. Lee, H.W. Lee,
K.C. Won, Inhibition of fatty acid translocase cluster determinant 36 (CD36),
stimulated by hyperglycemia, prevents glucotoxicity in INS-1 cells, Biochem.
Biophys. Res. Commun. 420 (2012) 462–466.
[11] H. Noushmehr, E. D'Amico, L. Farilla, et al., Fatty acid translocase (FAT/CD36) is
localized on insulin-containing granules in human pancreatic beta-cells and
mediates fatty acid eﬀects on insulin secretion, Diabetes 54 (2005) 472–481.
[12] T. Wallin, Z. Ma, H. Ogata, et al., Facilitation of fatty acid uptake by CD36 in
insulin-producing cells reduces fatty-acid-induced insulin secretion and glucose
regulation of fatty acid oxidation, Biochim. Biophys. Acta 1801 (2010) 191–197.
[13] X. Chi, S. Wang, Y. Huang, et al., Roles of rho GTPases in intracellular transport
and cellular transformation, Int. J. Mol. Sci. 14 (2013) 7089–7108.
[14] M.C. Dinauer, Regulation of neutrophil function by Rac GTPases, Curr. Opin.
Hematol. 10 (2003) 8–15.
[15] A. Kowluru, Friendly, and not so friendly, roles of Rac1 in islet beta-cell function:
lessons learnt from pharmacological and molecular biological approaches,
Biochem. Pharmacol. 81 (2011) 965–975.
[16] P. Newsholme, D. Morgan, E. Rebelato, H.C. Oliveira-Emilio, J. Procopio, R. Curi,
et al., Insights into the critical role of NADPH oxidase(s) in the normal and
dysregulated pancreatic beta cell, Diabetologia 52 (2009) 2489–2498.
[17] A. Panday, M.K. Sahoo, D. Osorio, S. Batra, NADPH oxidases: an overview from
structure to innate immunity-associated pathologies, Cell. Mol. Immunol. 12 (1)
(2014) 5–23.
[18] A.M. Mohammed, A. Kowluru, Activation of apocynin sensitive NADPH oxidase
(Nox2) activity in INS-1 832/13 cells under glucotoxic conditions, Islets 5 (3)
(2013) 129–131.
[19] U. Karunakaran, J.S. Moon, H.W. Lee, K.C. Won, CD36 initiated signaling mediates
ceramide-induced TXNIP expression in pancreatic beta-cells, Biochim. Biophys.
Acta 1852 (11) (2015) 2414–2422.
[20] U. Karunakaran, K.G. Park, A systematic review of oxidative stress and safety of
antioxidants in diabetes: focus on islets and their defense, Diabetes Metab. J. 37 (2)
(2013) 106–112.
[21] M. Aharoni-Simon, R. Shumiatcher, A. Yeung, A.Z. Shih, V.W. Dolinsky,
C.A. Doucette, D.S. Luciani, Bcl-2 regulates reactive oxygen species signaling and a
redox-sensitive mitochondrial proton leak in mouse pancreatic beta-cells,
Endocrinology 157 (6) (2016) 2270–2281.
[22] J.A. Wali, D. Rondas, M.D. McKenzie, Y. Zhao, L. Elkerbout, S. Fynch, et al., The
proapoptotic BH3-only proteins Bim and Puma are downstream of endoplasmic
reticulum and mitochondrial oxidative stress in pancreatic islets in response to
glucotoxicity, Cell Death Dis. 5 (2014) e1124.
[23] D. Morgan, H.R. Oliver-Emilio, D. Keane, A.E. Hirata, M. Santos da Rocha,
S. Bordin, et al., Glucose, palmitic and pro-inﬂammatory cytokines modulate
production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets
and a clonal cell line, Diabetologia 50 (2007) 359–369.
[24] A. Kowluru, Small G proteins in islet β-cell function, Endocr. Rev. 31 (2010) 52–78.
[25] J.L. Evans, I.D. Goldﬁne, B.A. Maddux, G.M. Grodsky, Are oxidative stress-
activated signaling pathways mediators of insulin resistance and β-cell dysfunc-
tion?, Diabetes 52 (2003) 1–8.
[26] P.L. Hordijk, Regulation of NADPH oxidases: the role of Rac proteins, Circ. Res. 98
(2006) 453–462.
[27] A. Abo, E. Pick, A. Hall, N. Totty, C.G. Teahan, A.W. Segal, Activation of the
NADPH oxidase involves the small GTP-binding protein p21rac1, Nature 353
(1991) 668–670.
[28] M. Chen, Y.K. Yang, T.J. Loux, K.E. Georgeson, C.M. Harmon, The role of
hyperglycemia in FAT/CD36 expression and function, Pediatr. Surg. Int. 22 (2006)
647–654.
[29]] J.H. Xue, Z. Yuan, Y. Wu, Y. Liu, Y. Zhao, W.P. Zhang, Y.L. Tian, W.M. Liu, Y. Liu,
C. Kishimoto, High glucose promotes intracellular lipid accumulation in vascular
smooth muscle cells by impairing cholesterol inﬂux and eﬄux balance, Cardiovasc.
Res. 86 (1) (2010) 141–150.
[30] M. Gharib, H. Tao, T.V. Fungwe, T. Hajri, Cluster Diﬀerentiating 36 (CD36)
deﬁciency attenuates obesity-associated oxidative stress in the heart, PLoS One 11
(5) (2016) e0155611.
[31] K. Koulajian, T. Desai, G.C. Liu, A. Ivovic, J.N. Patterson, C. Tang, et al., NADPH
oxidase inhibition prevents beta cell dysfunction induced by prolonged elevation of
oleate in rodents, Diabetologia 56 (2013) 1078–1087.
[32] P. Newsholme, E.P. Haber, S.M. Hirabara, E.L. Rebelato, J. Procopio, D. Morgan,
et al., Diabetes associated cell stress and dysfunction: role of mitochondrial and
non-mitochondrial ROS production and activity, J. Physiol. 583 (2007) 9–24.
[33] X. Men, H. Wang, M. Li, et al., Dynamin-related protein 1 mediates high glucose
induced pancreatic beta cell apoptosis, Int. J. Biochem. Cell Biol. 41 (2009)
879–890.
[34] D. Mokhtari, J.W. Myers, N. Welsh, The MAPK kinase kinase-1 is essential for
stress-induced pancreatic islet cell death, Endocrinology 149 (2008) 3046–3053.
[35] N. Hou, S. Torii, N. Saito, M. Hosaka, T. Takeuchi, Reactive oxygen species-
mediated pancreatic beta-cell death is regulated by interactions between stress-
activated protein kinases, p38 and c-Jun N-terminal kinase, and mitogen-activated
protein kinase phosphatases, Endocrinology 149 (2008) 1654–1665.
[36] V. Sidarala, R. Veluthakal, K. Syeda, C. Vlaar, P. Newsholme, A. Kowluru,
Phagocyte-like NADPH oxidase (Nox2) promotes activation of p38MAPK in
pancreatic β-cells under glucotoxic conditions: Evidence for a requisite role of Ras-
related C3 botulinum toxin substrate 1 (Rac1), Biochem. Pharmacol. 95 (4) (2015)
301–310.
S. Elumalai et al. Redox Biology 11 (2017) 126–134
134
